Computational Characterization of Ceftriaxone and Novel Compounds in Opioid Use Disorder: Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulations

Opioid use disorder (OUD) is a global issue characterized by compulsive opioid use and is linked to significant morbidity and mortality. Ceftriaxone has been investigated for its potential neuroprotective and immunomodulatory effects; however, its mechanisms in opioid dependence remain unclear. This study employed a network pharmacological approach to explore the potential molecular target of ceftriaxone and related signaling pathways in OUD. Targets were identified based on a comparative toxicogenomics database, SwissTargetPrediction, complemented by PharmMapper for ceftriaxone and GeneCards and Gene Expression Omnibus for OUD. Overlapping targets were identified using Venn diagrams and analyzed via the STRING platform to construct a protein–protein interaction network. Biological insights were sourced from the DAVID database, and Gene Ontology and KEGG pathway enrichment evaluated the biological significance of the target genes using Metascape. Molecular docking was performed using AutoDock Vina (version 1.1.1) for ceftriaxone, its analogs, and other GLT-1 modulators: MC-100093, MC-350012, MC-350013, and MC-290401. A total of 10 overlapping genes (IL-1β, TNF, ALB, EGFR, ESR1, CDK5, MME, SLC1A2, EPO, and SRC) were identified with multiple biological functions and signaling pathways. Molecular docking predicted that the novel GLT-1 modulator, MC-350013, exhibited favorable docking scores toward several prioritized proteins, particularly ESR1, EGFR, IL-1β, and ALB. Molecule 13 also demonstrated favorable docking scores for the selected proteins. Molecular dynamics simulations characterized the interaction behavior of the novel GLT-1 modulator, MC-350012 and MC-350013. Although ceftriaxone showed stronger hydrogen-bonding interactions, MC-350012 and MC-350013 showed favorable predicted interaction profiles with IL-1β and ESR1. Collectively, these computational findings may suggest MC-350012 and MC-350013 as candidates for further experimental investigation based on their predicted interactions with key OUD-related targets.

Authors

Institutions

Publication Details

Journal
Current Issues in Molecular Biology
Published
2026-11-16
DOI
https://doi.org/10.3390/cimb48111231
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Computational Characterization of Ceftriaxone and Novel Compounds in Opioid Use Disorder: Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulations

Magid A. Abou-Gharbia, Faizul Azam, Qamraa Hamad Alqahtani, Wayne E. Childers et al.
3 links
Current Issues in Molecular Biology
Computational Drug Discovery Methods
article

Computational Characterization of Ceftriaxone and Novel Compounds in Opioid Use Disorder: Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulations

Magid A. Abou-Gharbia, Faizul Azam, Qamraa Hamad Alqahtani, Wayne E. Childers, Abdullah F. Alasmari, Youssef Sari, Rawan Saleh Alsikhan, Mohammed M. Alshehri, Thikra Algahtani, Fawaz F. Alasmari, Sarah T. Binakeel, Hala H. Alrefashy
article en

Abstract

Opioid use disorder (OUD) is a global issue characterized by compulsive opioid use and is linked to significant morbidity and mortality. Ceftriaxone has been investigated for its potential neuroprotective and immunomodulatory effects; however, its mechanisms in opioid dependence remain unclear. This study employed a network pharmacological approach to explore the potential molecular target of ceftriaxone and related signaling pathways in OUD. Targets were identified based on a comparative toxicogenomics database, SwissTargetPrediction, complemented by PharmMapper for ceftriaxone and GeneCards and Gene Expression Omnibus for OUD. Overlapping targets were identified using Venn diagrams and analyzed via the STRING platform to construct a protein–protein interaction network. Biological insights were sourced from the DAVID database, and Gene Ontology and KEGG pathway enrichment evaluated the biological significance of the target genes using Metascape. Molecular docking was performed using AutoDock Vina (version 1.1.1) for ceftriaxone, its analogs, and other GLT-1 modulators: MC-100093, MC-350012, MC-350013, and MC-290401. A total of 10 overlapping genes (IL-1β, TNF, ALB, EGFR, ESR1, CDK5, MME, SLC1A2, EPO, and SRC) were identified with multiple biological functions and signaling pathways. Molecular docking predicted that the novel GLT-1 modulator, MC-350013, exhibited favorable docking scores toward several prioritized proteins, particularly ESR1, EGFR, IL-1β, and ALB. Molecule 13 also demonstrated favorable docking scores for the selected proteins. Molecular dynamics simulations characterized the interaction behavior of the novel GLT-1 modulator, MC-350012 and MC-350013. Although ceftriaxone showed stronger hydrogen-bonding interactions, MC-350012 and MC-350013 showed favorable predicted interaction profiles with IL-1β and ESR1. Collectively, these computational findings may suggest MC-350012 and MC-350013 as candidates for further experimental investigation based on their predicted interactions with key OUD-related targets.

Current Issues in Molecular BiologyVol. 48(11)
Qassim University (SA), King's College London (GB), King Saud University (SA), Temple University (US), University of Toledo (US)
King Saud University
Good health and well-being
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon